Based on the findings from the 2022 AUA global survey and needs assessment in bladder cancer, the AUA has developed this new series of virtual courses to update urologists on the latest advancements in bladder cancer care. This course will address new and emerging treatment options for non‐muscle invasive (NMIBC) and muscle‐invasive bladder cancer (MIBC) with a focus on identifying side effects and interventions, review of guidelines specific to first and second line therapies, timing and usage of neoadjuvant and adjuvant systemic therapy, BCG shortage and the urologists role in clinical trial enrollment. Currently available agents as well as those in development will be discussed.

CME Available: https://auau.auanet.org/node/38615

Release Date: June, 2023

Expiration Date: June, 2024

ACKNOWLEDGEMENTS

This educational series is supported by an independent educational grant from AstraZeneca.

After participating in this educational series, participants will be able to:

1. Delineate key factors to risk stratify patients with NMIBC and MIBC.

2. Review guidelines focused on first‐ and second‐line therapies for NMIBC and MIBC.

3. Describe emerging treatment options with intravesical and systemic therapies for patients in an era of BCG shortage and for patients with BCG unresponsive disease and determine the appropriate timing and use of neoadjuvant and adjuvant systemic therapy for invasive bladder cancer.

4. Identify side effects and possible interventions to ameliorate side effects for these therapies.

5. Recognize the urologist’s role in clinical trials and how to overcome obstacles to clinical trial enrollment.